Amicus

In anticipation of PhIII trial results, Amicus pares down old debt with $400 million loan
In anticipation of PhIII trial results, Amicus pares down old debt with $400 million loan
Endpoints
Amicus
Pompe disease
clinical trials
Flag link:
Pompe Disease Patients on Amicus Drug Continue to Improve in Study
Pompe Disease Patients on Amicus Drug Continue to Improve in Study
Xconomy
Pompe disease
Amicus
ABT200
Flag link:
Amicus CEO directly lobbied FDA’s Gottlieb to reverse FDA’s rejection of migalastat, claiming a delay of up to 7 years
Amicus CEO directly lobbied FDA’s Gottlieb to reverse FDA’s rejection of migalastat, claiming a delay of up to 7 years
Endpoints
Amicus
Pharma CEOs
FDA
Scott Gottlieb
migalastat
Fabry disease
Flag link:
Amicus’s Scioderm Deal Flops as Skin Drug Fails in Phase 3
Amicus’s Scioderm Deal Flops as Skin Drug Fails in Phase 3
Xconomy
Amicus
Scioderm
clinical trials
epidermolysis bullosa
Flag link:
Amicus CEO John Crowley, Not His Daughter Megan, Might Compel Trump to Make Big Changes at FDA
Amicus CEO John Crowley, Not His Daughter Megan, Might Compel Trump to Make Big Changes at FDA
TheStreet.com
Amicus
Pharma CEOs
John Crowley
Rare Diseases
Donald Trump
FDA
Flag link:
On second thought, Amicus won't be filing its lead drug this year
On second thought, Amicus won't be filing its lead drug this year
Fierce Biotech
Amicus
FDA
migalastat
Fabry's disease
Flag link:
Why Genzyme isn't worried about a threat by Amicus to its next Fabry drug
Why Genzyme isn't worried about a threat by Amicus to its next Fabry drug
Bizjournals.com
Genzyme
Amicus
Fabry's disease
Cerezyme
Fabrazyme
Sanofi
Flag link:
Amicus' rare disease drug lines up for a quick EU approval
Amicus' rare disease drug lines up for a quick EU approval
Fierce Biotech
Amicus
Europe
migalastat
Fabry's disease
Flag link:
Yes, Call it a Comeback: Amicus Fabry Drug Posts Big Study Win
Yes, Call it a Comeback: Amicus Fabry Drug Posts Big Study Win
TheStreet.com
Fabry's disease
Amicus
Migalastat HCl
GSK
Flag link:
Busy Biogen Idec fuels Amicus in Parkinson's drug chase
Busy Biogen Idec fuels Amicus in Parkinson's drug chase
Fierce Biotech
Biogen Idec
Amicus
Parkinson's Disease
Flag link:
Amicus Delays U.S. Approval Filing for Fabry Disease Drug
Amicus Delays U.S. Approval Filing for Fabry Disease Drug
TheStreet.com
Fabry's disease
Amicus
GSK
Amigal
Flag link:
A Legit Reason To Give Amicus' Fabry Drug Another Chance
A Legit Reason To Give Amicus' Fabry Drug Another Chance
TheStreet.com
Amicus
Fabry's disease
Amigal
Flag link:
Orphan Drug Mania: Amicus / Migalastat HCl
Orphan Drug Mania: Amicus / Migalastat HCl
Seeking Alpha
Amicus
Migalastat HCl
orphan drugs
Fabry's disease
Flag link:
A Triple Play Of Biotech Disappointments Last Week
A Triple Play Of Biotech Disappointments Last Week
Investopedia
Amicus
Hemispherx Biopharma
GSK
Oncothyreon
Flag link:
Amicus Fabry Drug Fails Pivotal Trial
Amicus Fabry Drug Fails Pivotal Trial
TheStreet.com
Amicus
Fabry's disease
Amigal
GSK
Flag link:
Amicus Soon To Release New Phase III Data
Amicus Soon To Release New Phase III Data
Seeking Alpha
Amicus
AT1001
Amigal
Migalastat HCl
Fabry's disease
Flag link:
Amicus: Bullish Options Trade Into Clinical Trial Catalysts
Amicus: Bullish Options Trade Into Clinical Trial Catalysts
TheStreet.com
Amicus
clinical trials
Amigal
Flag link:
Several Biopharmas That Look Ready For Upside Gains
Several Biopharmas That Look Ready For Upside Gains
Yahoo/Reuters
Sarepta
BG Medicine
Amicus
Santarus
Celldex
Flag link:
Parkinson's Disease: 3 Different Firms, 3 Novel Approaches
Parkinson's Disease: 3 Different Firms, 3 Novel Approaches
Seeking Alpha
Parkinson's Disease
Amicus
Impax Laboratories
International Stem Cell Corp
Flag link:
Amicus: GlaxoSmithKline And Insiders Are Heavily Buying This Stock
Amicus: GlaxoSmithKline And Insiders Are Heavily Buying This Stock
Seeking Alpha
GSK
Amicus
Flag link: